Figure 7—figure supplement 1.

Figure 7—figure supplement 1.

(A) Adapted dihydropyridine cluster including compounds not represented in the Tocris or Spectrum collections. The new compounds tested are shown as green circles. Nemadipine-A falls just below the threshold of the network analysis performed, illustrated by the dotted line connecting to its closest related compound. (B) Dose-responsive activity of the dihydropyridines in the vcanb assay. (i-xii) Lateral views of the inner ear at four dpf stained for vcanb by ISH; anterior to the left. Controls: (i) wild-type, untreated; (vii) adgrg6^tb233c mutant treated with DMSO as a negative control; (xii) adgrg6^tb233c mutant treated with 100 µM IBMX as a positive control. (ii-vi) Treatment of adgrg6^tb233c mutants with test compounds at a low concentration (25–33.8 µM), (viii-xi) treatment of adgrg6^tb233c mutants with test compounds at a high concentration (40–50.6 µM), (xiii-xvii) Representation of the chemical structure of the five compounds tested. Scale bar in (i), 50 µm (applies to i-xii).